Diagnostic performance of commercially available COVID-19 serology tests in Brazil. International Journal of Infectious Diseases

Detalhes bibliográficos
Autor(a) principal: Cota, Gláucia Fernandes
Data de Publicação: 2020
Outros Autores: Freire, Mariana Lourenço, Souza, Carolina Senra de, Pedras, Mariana Junqueira, Saliba, Juliana Wilke, Faria, Verônica, Alves, Líndicy Leidicy, Rabello, Ana Lucia Teles, Avelar, Daniel Moreira
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/51675
Resumo: Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
id CRUZ_a9e2ce05deb5eb4ca03b51e624dd341a
oai_identifier_str oai:www.arca.fiocruz.br:icict/51675
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Cota, Gláucia FernandesFreire, Mariana LourençoSouza, Carolina Senra dePedras, Mariana JunqueiraSaliba, Juliana WilkeFaria, VerônicaAlves, Líndicy LeidicyRabello, Ana Lucia TelesAvelar, Daniel Moreira2022-03-10T14:36:37Z2022-03-10T14:36:37Z2020COTA, Glaucia Fernandes et al. Diagnostic performance of commercially available COVID-19 serology tests in Brazil. International Journal of Infectious Diseases. International Journal of Infectious Diseases, p. 1-37, 2020.1201-9712https://www.arca.fiocruz.br/handle/icict/5167510.1016/j.ijid.2020.10.008Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.Timely and accurate laboratory testing is essential to manage the global COVID-19 pandemic. Reverse transcription-polymerase chain reaction remains the gold-standard for SARS-CoV-2 diagnosis, but several practical issues limit the test use. Immunoassays have been indicated as an alternative for individual and mass testing. Objectives: To access the performance of twelve serological tests for COVID-19 diagnosis. Methods: We conducted a blind evaluation of six lateral flow immune assays (LFIAs) and six enzyme-linked immunosorbent assays (ELISA) commercially available in Brazil to detect anti-SARS-CoV-2 antibodies. Results: Considering patients with seven or more days of symptoms, the sensitivity ranged from 59.5% to 83.1% for LFIAs and from 50.7% to 92.6% for ELISAs. For both methods, the sensitivity increased with clinical severity and days of symptoms. The agreement between LFIA performed in digital blood and serum was moderate. Specificity was, in general, higher for LFIAs than for ELISAs. Infectious diseases prevalent in the tropics, such as HIV, leishmaniasis, arboviruses and malaria, represent conditions with the potential to cause false positive results, which significantly compromises their specificity. Conclusion: The performance of immunoassays was only moderate, affected by the duration and clinical severity of the disease. Absence of discriminatory power between IgM/IgA and IgG has also been demonstrated, which prevents the use of acute phase antibodies for decisions on social isolation.engElsevierhttps://www.arca.fiocruz.br/handle/icict/44107Diagnostic performance of commercially available COVID-19 serology tests in Brazil. International Journal of Infectious Diseasesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleAntibodyCOVID-19PerformanceSARS-CoV-2Rapid testSerologyDiagnosisAccuracyinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83082https://www.arca.fiocruz.br/bitstream/icict/51675/1/license.txt9193a7c197bc67acd023525e72a03240MD51ORIGINALCota_Gláucia_etal_IRR_2020_COVID-19_Artigo_Final.pdfCota_Gláucia_etal_IRR_2020_COVID-19_Artigo_Final.pdfapplication/pdf504738https://www.arca.fiocruz.br/bitstream/icict/51675/2/Cota_Gl%c3%a1ucia_etal_IRR_2020_COVID-19_Artigo_Final.pdf21ae9f55fec5c1d69e0ea686f11de905MD52icict/516752022-03-17 20:27:46.284oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-03-17T23:27:46Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Diagnostic performance of commercially available COVID-19 serology tests in Brazil. International Journal of Infectious Diseases
title Diagnostic performance of commercially available COVID-19 serology tests in Brazil. International Journal of Infectious Diseases
spellingShingle Diagnostic performance of commercially available COVID-19 serology tests in Brazil. International Journal of Infectious Diseases
Cota, Gláucia Fernandes
Antibody
COVID-19
Performance
SARS-CoV-2
Rapid test
Serology
Diagnosis
Accuracy
title_short Diagnostic performance of commercially available COVID-19 serology tests in Brazil. International Journal of Infectious Diseases
title_full Diagnostic performance of commercially available COVID-19 serology tests in Brazil. International Journal of Infectious Diseases
title_fullStr Diagnostic performance of commercially available COVID-19 serology tests in Brazil. International Journal of Infectious Diseases
title_full_unstemmed Diagnostic performance of commercially available COVID-19 serology tests in Brazil. International Journal of Infectious Diseases
title_sort Diagnostic performance of commercially available COVID-19 serology tests in Brazil. International Journal of Infectious Diseases
author Cota, Gláucia Fernandes
author_facet Cota, Gláucia Fernandes
Freire, Mariana Lourenço
Souza, Carolina Senra de
Pedras, Mariana Junqueira
Saliba, Juliana Wilke
Faria, Verônica
Alves, Líndicy Leidicy
Rabello, Ana Lucia Teles
Avelar, Daniel Moreira
author_role author
author2 Freire, Mariana Lourenço
Souza, Carolina Senra de
Pedras, Mariana Junqueira
Saliba, Juliana Wilke
Faria, Verônica
Alves, Líndicy Leidicy
Rabello, Ana Lucia Teles
Avelar, Daniel Moreira
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Cota, Gláucia Fernandes
Freire, Mariana Lourenço
Souza, Carolina Senra de
Pedras, Mariana Junqueira
Saliba, Juliana Wilke
Faria, Verônica
Alves, Líndicy Leidicy
Rabello, Ana Lucia Teles
Avelar, Daniel Moreira
dc.subject.en.pt_BR.fl_str_mv Antibody
COVID-19
Performance
SARS-CoV-2
Rapid test
Serology
Diagnosis
Accuracy
topic Antibody
COVID-19
Performance
SARS-CoV-2
Rapid test
Serology
Diagnosis
Accuracy
description Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
publishDate 2020
dc.date.issued.fl_str_mv 2020
dc.date.accessioned.fl_str_mv 2022-03-10T14:36:37Z
dc.date.available.fl_str_mv 2022-03-10T14:36:37Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv COTA, Glaucia Fernandes et al. Diagnostic performance of commercially available COVID-19 serology tests in Brazil. International Journal of Infectious Diseases. International Journal of Infectious Diseases, p. 1-37, 2020.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/51675
dc.identifier.issn.pt_BR.fl_str_mv 1201-9712
dc.identifier.doi.none.fl_str_mv 10.1016/j.ijid.2020.10.008
identifier_str_mv COTA, Glaucia Fernandes et al. Diagnostic performance of commercially available COVID-19 serology tests in Brazil. International Journal of Infectious Diseases. International Journal of Infectious Diseases, p. 1-37, 2020.
1201-9712
10.1016/j.ijid.2020.10.008
url https://www.arca.fiocruz.br/handle/icict/51675
dc.language.iso.fl_str_mv eng
language eng
dc.relation.isversionof.pt_BR.fl_str_mv https://www.arca.fiocruz.br/handle/icict/44107
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/51675/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/51675/2/Cota_Gl%c3%a1ucia_etal_IRR_2020_COVID-19_Artigo_Final.pdf
bitstream.checksum.fl_str_mv 9193a7c197bc67acd023525e72a03240
21ae9f55fec5c1d69e0ea686f11de905
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813008865586839552

Registros relacionados